Clinical Trials Logo

Clinical Trial Summary

The CUV156 study will evaluate the safety of afamelanotide in XP-C patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05159752
Study type Interventional
Source Clinuvel Pharmaceuticals Limited
Contact Head of Clinical Operations
Phone +441372860765
Email mail@clinuvel.com
Status Recruiting
Phase Phase 2
Start date October 19, 2021
Completion date October 2024

See also
  Status Clinical Trial Phase
Completed NCT00555633 - Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients N/A
Recruiting NCT05484570 - Natural History Study for DNA Repair Disorders
Active, not recruiting NCT00001813 - Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
Completed NCT03445052 - XPAND Trial: Enhancing XP Photoprotection Activities - New Directions N/A
Recruiting NCT05370235 - A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V Phase 2
Unknown status NCT01123694 - Xeroderma Pigmentosum Patient Experiences N/A
Withdrawn NCT04500548 - Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Phase 1
Enrolling by invitation NCT06330324 - Reproductive Options in Inherited Skin Diseases
Completed NCT00046189 - Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum